Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial

In randomised trials of medical interventions, the most reliable analysis follows the intention-to-treat (ITT) principle. However, the ITT analysis requires that missing outcome data have to be imputed. Different imputation techniques may give different results and some may lead to bias. In anti-obe...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 11; p. e111964
Main Authors Jørgensen, Anders W, Lundstrøm, Lars H, Wetterslev, Jørn, Astrup, Arne, Gøtzsche, Peter C
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 19.11.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In randomised trials of medical interventions, the most reliable analysis follows the intention-to-treat (ITT) principle. However, the ITT analysis requires that missing outcome data have to be imputed. Different imputation techniques may give different results and some may lead to bias. In anti-obesity drug trials, many data are usually missing, and the most used imputation method is last observation carried forward (LOCF). LOCF is generally considered conservative, but there are more reliable methods such as multiple imputation (MI). To compare four different methods of handling missing data in a 60-week placebo controlled anti-obesity drug trial on topiramate. We compared an analysis of complete cases with datasets where missing body weight measurements had been replaced using three different imputation methods: LOCF, baseline carried forward (BOCF) and MI. 561 participants were randomised. Compared to placebo, there was a significantly greater weight loss with topiramate in all analyses: 9.5 kg (SE 1.17) in the complete case analysis (N = 86), 6.8 kg (SE 0.66) using LOCF (N = 561), 6.4 kg (SE 0.90) using MI (N = 561) and 1.5 kg (SE 0.28) using BOCF (N = 561). The different imputation methods gave very different results. Contrary to widely stated claims, LOCF did not produce a conservative (i.e., lower) efficacy estimate compared to MI. Also, LOCF had a lower SE than MI.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Conceived and designed the experiments: AWJ JW PCG. Performed the experiments: AA. Analyzed the data: AWJ LHL JW. Contributed reagents/materials/analysis tools: AA. Wrote the paper: AWJ. Contributed to writing the paper: LHL JW AA PCG.
Competing Interests: This trial was supported by Johnson & Johnson Pharmaceutical Research and Development, LLP, the producer of topiramate, to conduct the clinical trial from which the data for this paper originated (see reference 10). Arne Astrup is currently consultant or member of advisory boards for a number companies, including: Arena Pharmaceuticals Inc., USA; Basic Research, USA; BioCare Copenhagen, DenmarK; Boehringer Ingelheim Pharma, Germany; Gelesis, USA; Novo Nordisk, Denmark; Pathway Genomics Corporation, USA; S-Biotek, Denmark; Twinlab, USA; Vivus Inc., USA. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0111964